BNT 317
Alternative Names: BNT-317Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator BioNTech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 13 Jan 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (IV) (NCT06750185)
- 27 Dec 2024 BioNTech plans a phase I trial for Solid tumors (Late-stage disease) (IV, Infusion) in January 2025 (NCT06750185)
- 27 Dec 2024 Preclinical trials in Solid tumours in Germany (IV) prior to December 2024